E-CEL UVEC(E-CEL UVEC) - 在研适应症：肛裂，瘘，肌肉萎缩_专利_临床

概要

基本信息

药物类型

基因疗法、干细胞疗法

别名-

靶点-

作用机制

细胞替代物

治疗领域

神经系统疾病消化系统疾病其他疾病

在研适应症

肛裂瘘肌肉萎缩+ [2]

非在研适应症-

原研机构

Angiocrine Bioscience, Inc.

在研机构

Angiocrine Bioscience, Inc.

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 E-CEL UVEC 相关的临床试验

NCT06456073 / Recruiting临床1期IIT

An Open-Label, Single-Center, Investigator Initiated Phase 1B Trial of E-CEL UVEC Cell Therapy for the Treatment of Chronic Anal Fissure

This clinical trial is being conducted by investigators who are colorectal surgeons. Eligible study participants will receive the experimental treatment E-CEL UVEC cells by direct injection into the anal fissure. The study is being conducted to determine if E-CEL UVEC cell injections will be safe and would have any effects on healing of the anal fissure.

开始日期2024-09-01

申办/合作机构

Weill Medical College of Cornell University

[+1]

NCT04190862 / Recruiting临床1期IIT

An Open-Label, Single-Center, Investigator Initiated Phase 1B Trial of E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas

The purpose of this study is to determine if endothelial cells derived from human umbilical vein are safe for use in conjunction with fistulotomy for the treatment of simple anal fistulas. Endothelial cells are a special kind of cell in the body that line the inside surface of blood vessels. The goal of the study is to evaluate the preliminary safety of human umbilical vein cells in anal fistula healing.

开始日期2020-01-22

申办/合作机构

Weill Medical College of Cornell University

[+1]

NCT04057833 / Active, not recruiting临床1期IIT

A Phase 1 Open-Label, Single-Center Investigator Initiated Trial (IIT) of E-CEL UVEC Cells as an Adjunct Cell Therapy for the Arthroscopic Rotator Cuff Repair in Adults

This is a phase 1b investigator-initiated clinical trial that will evaluate the safety and feasibility of E-CEL UVEC® cells with the aim of improving outcomes for patients with full-thickness rotator cuff tears who undergo arthroscopic surgical repair.
Allogeneic E-CEL UVEC cells will be delivered to the tendon repair site and to the muscle adjacent to the tendon repair site.

开始日期2019-11-20

申办/合作机构

Hospital for Special Surgery

[+1]

100 项与 E-CEL UVEC 相关的临床结果

登录后查看更多信息

100 项与 E-CEL UVEC 相关的转化医学

登录后查看更多信息

100 项与 E-CEL UVEC 相关的专利（医药）

登录后查看更多信息

100 项与 E-CEL UVEC 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肛裂	临床1期	美国	Angiocrine Bioscience, Inc.	2024-09-01
瘘	临床1期	美国	Angiocrine Bioscience, Inc.	2020-01-22
肌肉萎缩	临床1期	美国	Angiocrine Bioscience, Inc.	2019-11-20
肩袖肌腱炎	临床1期	美国	Angiocrine Bioscience, Inc.	2019-11-20
破裂	临床1期	美国	Angiocrine Bioscience, Inc.	2019-11-20